Fusion Pharmaceuticals Inc. Comprehensive Income
Fusion Pharmaceuticals Inc. reported Comprehensive Income of -$34.49 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2024-05-07
- Fusion Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-03-31 was -$34.49M.
- Fusion Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-12-31 was -$27.10M.
- Fusion Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-09-30 was -$17.84M.
- Fusion Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-06-30 was -$25.34M.
- Fusion Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$94.19M.
- Fusion Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$87.97M.
- Fusion Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$81.21M.
- Fusion Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$78.29M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$34.49M 10-Q · filed 2024-05-07 | -$61.59M derived: sum of 2 quarters · filed 2024-05-07 | -$79.43M derived: sum of 3 quarters · filed 2024-05-07 | -$104.77M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | -$27.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$44.94M derived: sum of 2 quarters · filed 2024-03-20 | -$70.28M derived: sum of 3 quarters · filed 2024-03-20 | -$94.19M 10-K · filed 2024-03-20 |
| 2023-09-30 | -$17.84M 10-Q · filed 2023-11-07 | -$43.18M derived: sum of 2 quarters · filed 2023-11-07 | -$67.09M 10-Q · filed 2023-11-07 | -$90.92M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | -$25.34M 10-Q · filed 2023-08-08 | -$49.25M 10-Q · filed 2023-08-08 | -$73.08M derived: sum of 3 quarters · filed 2024-05-07 | -$97.29M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | -$23.91M 10-Q · filed 2024-05-07 | -$47.74M derived: sum of 2 quarters · filed 2024-05-07 | -$71.95M derived: sum of 3 quarters · filed 2024-05-07 | -$91.50M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$23.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$48.04M derived: sum of 2 quarters · filed 2024-03-20 | -$67.59M derived: sum of 3 quarters · filed 2024-03-20 | -$87.97M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$24.21M 10-Q · filed 2023-11-07 | -$43.76M derived: sum of 2 quarters · filed 2023-11-07 | -$64.14M 10-Q · filed 2023-11-07 | -$81.55M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$19.55M 10-Q · filed 2023-08-08 | -$39.93M 10-Q · filed 2023-08-08 | -$57.34M derived: sum of 3 quarters · filed 2023-08-08 | -$77.04M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$20.37M 10-Q · filed 2023-05-11 | -$37.79M derived: sum of 2 quarters · filed 2023-05-11 | -$57.49M derived: sum of 3 quarters · filed 2023-05-11 | -$84.29M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$17.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$37.12M derived: sum of 2 quarters · filed 2023-03-16 | -$63.92M derived: sum of 3 quarters · filed 2023-03-16 | -$81.21M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$19.70M 10-Q · filed 2022-11-08 | -$46.50M derived: sum of 2 quarters · filed 2022-11-08 | -$63.79M 10-Q · filed 2022-11-08 | -$77.13M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$26.80M 10-Q · filed 2022-08-09 | -$44.09M 10-Q · filed 2022-08-09 | -$57.43M derived: sum of 3 quarters · filed 2022-08-09 | -$67.42M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$17.29M 10-Q · filed 2022-05-10 | -$30.63M derived: sum of 2 quarters · filed 2022-05-10 | -$40.62M derived: sum of 3 quarters · filed 2022-05-10 | -$85.36M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$13.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$23.33M derived: sum of 2 quarters · filed 2022-03-17 | -$68.07M derived: sum of 3 quarters · filed 2022-03-17 | -$78.29M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$9.99M 10-Q · filed 2021-11-09 | -$54.73M derived: sum of 2 quarters · filed 2021-11-09 | -$64.95M 10-Q · filed 2021-11-09 | -$73.16M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$44.73M 10-Q · filed 2021-08-10 | -$54.95M 10-Q · filed 2021-08-10 | -$63.16M derived: sum of 3 quarters · filed 2021-08-10 | -$63.76M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$10.22M 10-Q · filed 2021-05-11 | -$18.43M derived: sum of 2 quarters · filed 2021-05-11 | -$19.02M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$8.80M derived: sum of 2 quarters · filed 2021-03-25 | -$16.19M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$594.00K 10-Q · filed 2020-11-10 | -$7.98M 10-Q · filed 2020-11-10 |